Article

Bimatoprost effective in patients with POAG, hypertension

Author(s):

Chet Scerra

Fort Lauderdale, FL-Bimatoprost appears to have greater IOP-lowering effectiveness than travoprost in patients with primary open-angle glaucoma (POAG) or ocular hypertension, according to a small pilot study.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
Related Content
KAIST announces new microbe development for lutein production
July 15th 2025

KAIST announces new microbe development for lutein production

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

New RainDrop Dispenser Aid aims to simplify use of single-use eye drops
July 15th 2025

New RainDrop Dispenser Aid aims to simplify use of single-use eye drops

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

MidWest Eye Center among first in Midwest to adopt new noncontact laser for glaucoma
July 15th 2025

MidWest Eye Center among first in Midwest to adopt new noncontact laser for glaucoma

Nanoscope Therapeutics initiates rolling submission of BLA to FDA for MCO-010
July 14th 2025

Nanoscope Therapeutics initiates rolling submission of BLA to FDA for MCO-010

© 2025 MJH Life Sciences

All rights reserved.